Posts tagged: pharmaceuticals
Idenix Pharmaceuticals makes progress with its HCV development pipeline
Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced the advancement of its hepatitis C virus development pipeline.
Merck selects Idera Pharmaceuticals’ TLR agonists for evaluation, use as vaccine adjuvant candidates
Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.
Marinus Pharmaceuticals Experimental Epilepsy Treatment Shows Promise In Open-Label Extension Study
Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company, announced that its neurosteroid ganaxolone which is currently under study for the treatment of partial onset seizures (POS), reported positive data in the open-label extension follow up to the company's Phase 2 clinical trial. The data reflects the replication of the effects ...
Merrimack Pharmaceuticals Initiates Enrollment In Phase 2 Study Of MM-121 In Combination With Erlotinib In Three Groups Of Patients With Lung Cancer
Merrimack Pharmaceuticals, Inc. announced that the first patient has been dosed in a Phase 2 clinical trial of MM-121, a fully human monoclonal antibody that targets ErbB3, in combination with erlotinib (Tarceva®), a small molecule directed at the epidermal growth factor receptor (EGFR), in three groups of patients with metastatic ...
Yissum Research and other investors complete additional investment round of $3 million in Avraham Pharmaceuticals
Yissum Research Development Company Ltd., the technology transfer arm of the Hebrew University of Jerusalem, today announced that it has participated in a U.S. $3 million financing round of Avraham Pharmaceuticals Ltd. together with Pontifax, Clal Biotechnology Industries (CBI), Technion Research and Development Foundation Ltd. (TRDF), Professor Marta Weinstock-Rosin and ...
Researchers Develop New Process With Porous Molecular Organic Frameworks (MOFs) – Relevant To The Production Of Pharmaceuticals
Researchers of Karlsruhe Institute of Technology (KIT) and Ruhr-Universitat Bochum (RUB) have developed a flexible and efficient new process for the separation of enantiomers. Enantiomer separation is indispensable for the production of many pharmaceuticals. In their process, the scientists use porous molecular frameworks (MOFs) that are assembled in layers on ...
Presidio Pharmaceuticals advances with its HCV antiviral drug discovery, development programs
Presidio Pharmaceuticals, Inc. today announced progress with its HCV antiviral drug discovery and development programs. A primary company objective is to advance multiple potent and safe inhibitors that target multiple HCV proteins and provide pan-genotypic coverage, as we believe such combination therapies will more adequately address the global medical need ...
FDA approves Endo Pharmaceuticals’ Felodipine Extended-release Tablets
Endo Pharmaceuticals today announced that the U.S. Food and Drug Administration has approved Felodipine Extended-release Tablets USP, 2.5mg, 5mg and 10mg.
Chiral Metal Surfaces May Help To Manufacture Pharmaceuticals
New research shows how metal surfaces that lack mirror symmetry could provide a novel approach towards manufacturing pharmaceuticals. These 'intrinsically chiral' metal surfaces offer potential new ways to control chiral chemistry, pointing to the intriguing possibility of using heterogeneous catalysis in drug synthesis. Such surfaces could also become the basis ...
Chiral metal surfaces may help to manufacture pharmaceuticals
(University of Cambridge) New research shows how metal surfaces that lack mirror symmetry could provide a novel approach towards manufacturing pharmaceuticals.
OncoGenex Pharmaceuticals Initiates An International, Randomized, Phase II Clinical Trial Evaluating OGX-427 In Advanced Bladder Cancer
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that it has initiated patient enrollment in a randomized, Phase II clinical trial evaluating OGX-427, an inhibitor of heat shock protein 27 (Hsp27), in patients with advanced bladder cancer. The trial is designed to assess the potential survival benefit of combining OGX-427 with ...